Valeant Pharmaceuticals International has pursued a plan in recent months to dominate the market for specialty contact lenses, according to two people familiar with the company’s approach and some of the company’s communications with its customers.
The Canadian drugmaker's goal, spelled out to key employees and demonstrated through its actions, has been to acquire other manufacturers, take on competitors and raise prices for unfinished lens components.
Antud sektoris on ka teisi firmasid, mis võivad pihta saada kui hakatakse uurima kontaktläätse äri. Rene Ilves
No comments:
Post a Comment